de Graeff, H.J.L
Rhythm Pharmaceuticals, the developer of setmelanotide, has successfully pursued regulatory approval for the drug (marketed as IMCIVREE) in conditions caused by upstream defects in the MC4R pathway, such as POMC and LEPR deficiencies, where the receptor itself is intact, and the agonist mechanism is highly effective [57]
This makes GLP-1s particularly valuable for patients with type 2 diabetes who are also at high risk for heart disease
These effects are often dose-related and may lessen as the body adjusts to the medication
When to reach out to your Care Team: If constipation lasts more than three days If it is accompanied by nausea, vomiting, or abdominal pain Seek immediate medical care if you experience severe pain, bloating with an inability to pass gas, or ongoing nausea and vomiting
The more transformative development is the imminent patent expiry of semaglutide in India in 2026